| Identification | Back Directory | [Name]
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) | [CAS]
2436747-41-8 | [Synonyms]
[1,1'-Biphenyl]-4-carboxamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-, hydrochloride (1:1) | [Molecular Formula]
C26H27Cl2N5O | [MOL File]
2436747-41-8.mol | [Molecular Weight]
496.44 |
| Hazard Information | Back Directory | [Uses]
BB-Cl-Amidine hydrochloride is a peptidylarginine deminase (PAD) inhibitor[1]. | [in vivo]
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely[1]. | Animal Model: | MRL/lpr mice[1]. | | Dosage: | 1 mg/kg. | | Administration: | Subcutaneous injection daily from 8 to 14 weeks of age. | | Result: | Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. |
| [References]
[1] Knight JS, et al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. 2015 Dec;74(12):2199-206. DOI:10.1136/annrheumdis-2014-205365 |
|
|